Skip to main content
. 2024 Mar 2;271(6):3471–3485. doi: 10.1007/s00415-024-12239-x

Table 3.

Mean OMDS in Cycle 2–Week 4, 8, and 12 and mean degree of improvement in Cycle 2–Week 4, 8, and 12 from baseline (full analysis set)

Mogamulizumab
n = 31
Placebo
n = 31
p value
Mean OMDS Mean ± SD 4.51 ± 0.99 4.63 ± 0.95
Mean degree of improvement in OMDS from baseline Mean ± SD 0.17 ± 0.37 0.24 ± 0.41
Difference (95% CI)  − 0.06 (− 0.26 to 0.13) 0.517

CI confidence interval, OMDS Osame motor disability score, SD standard deviation